A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 123 (planned)
- Started
- Jun 14, 2023
- Main results expected
- Aug 3, 2028
- Fully finished
- Aug 3, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Parts 1, 2 and 3: Number of Participants with any Adverse Event
Measured over: Up to 52 months
Part 1 (Dose escalation cohort) and Part 2: Number of Participants with Dose Limiting Toxicities (DLTs)
Measured over: Cycle 1 (Each cycle is of 28 days)
Part 1, 2 and 3: Number of Participants with Worst Case Grade Change from Baseline in Laboratory and Vital Sign Parameters
Measured over: Up to 52 months
Part 2: Number of Participants with severity of ocular events by the Keratopathy Visual Acuity (KVA) scale
Measured over: Up to 52 months
Part 2: Overall Response Rate (ORR)
Measured over: Up to 52 months
Part 3: Very Good Partial Response and better rate (VGPR+)
Measured over: Up to 52 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05714839 · record last updated 2026-08-19 · checked 2026-11-09 15:47 UTC